CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trials
Bitget2026/09/28 11:32- CervoMed disclosed Phase 1 study results for a new neflamapimod 50 mg tablet, positioning it for twice-daily dosing.
- The new formulation is intended to deliver steadier drug levels while reducing dosing frequency, addressing variability seen with the prior capsule.
- FDA lifted a prior plasma exposure cap, removing a key constraint on dose escalation in upcoming trials.
- Future clinical trials are planned to test a 100 mg twice-daily regimen, aiming for stronger expected activity with manageable tolerability.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
